Published • loading... • Updated
BioNTech to close sites in Germany, Singapore affecting 1,860 staff
The Mainz-based company is ending vaccine production as demand falls and will refocus on cancer research while closing sites in Germany and Singapore.
- BioNTech announced it will end in-house COVID-19 vaccine production, closing facilities in Idar-Oberstein, Marburg, Singapore, and Tübingen by the end of 2027 while leaving manufacturing to partner Pfizer.
- The restructuring follows a sharp decline in COVID vaccine demand, as revenues fell to roughly $138 million in the first quarter compared to €182.8 million in the same period last year.
- Up to 1,860 positions could be affected by the expanded restructuring, building on a prior plan announced last year to cut between 950 and 1,350 full-time roles, according to BioNTech.
- Co-Founders Ugur Sahin and Özlem Türeci announced in March they were stepping down to start a new venture, following the company's full takeover of rival CureVac in late 2025.
- BioNTech has retooled to prioritize research into cancer and other illnesses, including the Pumitamig antibody currently in phase 2 trials, while maintaining its main base in Mainz and offices in Berlin.
Insights by Ground AI
62 Articles
62 Articles
The focus of Biontech is on cancer medicine. This has consequences for the strategic orientation of Mainz - and the location Germany.
BioNTech, one of the first companies to develop a vaccine for Covid-19, will close out of production units, to be affected by up to 1,860 employees, notes Agerpres. Article The famous giant that closes factories on the treadmill. More than 1,800 employees remain unemployed first appears in Romania TV.
BioNTech to close sites in Germany, Singapore affecting 1,860 staff
BioNTech said on Tuesday it would close sites affecting up to 1,860 jobs and buy back up to $1 billion worth of its shares, as the COVID‑19 vaccine maker pivots away from pandemic-era manufacturing and prepares for a leadership transition.
·United Kingdom
Read Full Article
Coverage Details
Total News Sources62
Leaning Left6Leaning Right8Center10Last UpdatedBias Distribution42% Center
Bias Distribution
- 42% of the sources are Center
42% Center
L 25%
C 42%
R 33%
Factuality
To view factuality data please Upgrade to Premium
